ISPOR US 2023 | ICON plc

Thank you for speaking with the ICON team at ISPOR US 2023.

We invite you to explore the resources we have assembled to learn more about how we’re supporting our clients with integrated solutions to identify, generate, synthesise and communicate the outcomes evidence that regulators, payers, providers and patients need to make informed health decisions.

Contact us here for more information.

Whitepapers:

Keeping eCOA off a trial’s critical path

A best practice approach.

Survey results

How to engage healthcare decision-makers

Evidence Synthesis

A solution to sparse evidence, heterogeneous studies, and disconnected networks

Using longitudinal qualitative research to capture the patient voice

Methods for collecting, analysing, and reporting patients' perceptions of change over time

Ensuring scientific rigor in external control arms

Methodologies to support HTA decision making

Factsheets:

Patient Centered Outcomes

Interviews with patients in clinical trials

Rater training

An important consideration in clinical trial design

Patient Centricity

Integrating COAs and patient health data

Language Service

Full-service translation and clinical translation program management

ICON Market Access

Pricing, Market Access and Reimbursement

Mapi Research Trust: Facilitating access to Clinical Outcome Assessments (COA and eCOA) for the entire scientific community

ePROVIDE

The centralized platform to build your COA and eCOA strategies

Mapi Research Trust

Supporting developers and copyright holders with the strategic and operational management of their COAs

Mapi Research Trust and Rare Diseases

Specific expertise in Rare Diseases

Brochure:

Commercialisation & Outcomes

Your partner for insightful and pragmatic commercialisation and outcomes solutions

Webinar:

Medicare Part D Price Negotiation

Centers for Medicare & Medicaid Services (CMS) will begin negotiating with manufacturers on the price of Medicare Part D drugs beginning this year. In September, CMS will publish the list of 10 Part D selected drugs for negotiations. A key issue in the negotiations will be determination of the fair market price for a product. ICON panelists will bring their perspectives on critical issues around support for a product’s fair market price.

Watch on demand

Recent publications:

Patient and Caregiver Perceptions of Advanced Bladder Cancer Systemic Treatments

Finalization and Validation of Questionnaire and Algorithm of SPUR, a New Adherence Profiling Tool

Consultations for Influenza-Like Illness in Primary Care in The Netherlands: A Regression Approach

Cost-Effectiveness of Pediatric Influenza Vaccination in The Netherlands